ETHZilla Corporation Warrant
ATNFW
NASDAQ Capital Market0.43
USD
-0.03
- -
CIK
0001690080
ISIN
US68236V1127
CUSIP
68236V104
Return %
Stock
S&P500
1Y
6,515.38
26.53
3Y
343.30
76.60
5Y
58.61
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Lloyd Blair Jordan
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- Building 4 Palo Alto DE United States of America 94306
- IPO Date
- Jun 27, 2017
- CIK
- 0001690080
- Website
- 180lifesciences.com
- Similar Companies
- Business
- ETHZilla Corporation (Nasdaq: ETHZ), formerly 180 Life Sciences Corp., operates as an Ethereum accumulation vehicle and on-chain treasury management company that holds substantial Ether (ETH) reserves; implements differentiated yield generation strategies including staking, lending, liquidity provisioning, and bespoke private agreements through partnership with Electric Capital; maintains legacy biotechnology assets focused on anti-inflammatory therapeutics such as fibrosis inhibitors for Dupuytren’s Contracture, frozen shoulder, liver fibrosis (NASH), and post-operative cognitive decline, synthetic CBD analogs for early arthritis, pain, and obesity, and orally bioavailable anti-TNF therapies for ulcerative colitis and other inflammatory indications; and develops software-enabled iGaming and online entertainment platforms. The company, founded in 2016 and headquartered in Palo Alto, California, targets institutional investors, crypto-native participants, public market shareholders, healthcare patients with unmet inflammatory needs, and iGaming customers across the United States and international markets. In August 2025, ETHZilla completed a $425 million private placement of common stock and pre-funded warrants plus a $156.25 million convertible note offering, raising approximately $581 million gross proceeds from over 60 investors including Harbour Island Capital, Polychain Capital, GSR, Electric Capital, and prominent Ethereum founders; rebranded from 180 Life Sciences Corp. with common stock and warrants transitioning to tickers ETHZ and ETHZW on Nasdaq Capital Market, replacing prior ATNF and ATNFW; accumulated 94,675 ETH at an average price of $3,902.20 valued at about $419 million alongside $187 million in USD cash equivalents; appointed McAndrew Rudisill as Executive Chairman and added independent directors to its board and DeFi Council comprising Ethereum engineers and DeFi leaders; and executed a share repurchase of 1.318 million shares from Elray Resources and Luxor Capital to reduce dilution while advancing iGaming monetization and biotech IP realization.